TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02905656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate Reduction
Description: Reducing the number of cigarettes consumed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological
Description: Nicotine Replacement Therapy in the form of gum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological
Description: Nicotine Replacement Therapy in the form of gum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI+RR
Description: Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
Study: NCT00352443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
Study: NCT04723901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual target CAR-T cell therapy
Description: CD19/CD22 dual target CAR-T cell therapy
Study: NCT02462174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
Study: NCT01464294

Intervention type: DEVICE
Intervention: Milled ceramic restorations
Description: Restoration of back teeth with milled ceramic crowns or onlays

Intervention type: DEVICE
Intervention: Milled nano-composite restorations
Description: Restoration of back teeth with milled crowns or onlays
Study: NCT01900457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: approaches from psychophysics
Study: NCT02406950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
Study: NCT03799211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Phone call using motivational interviewing technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: will receive a regular study phone call after three months
Study: NCT03722771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhalation
Description: lavender oil inhalation in a separate room for 3 minutes prior to surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety Questionnaires 1
Description: Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaires 1
Description: Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety Questionnaires 2
Description: State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaires 2
Description: State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 1
Description: Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 1
Description: Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 2
Description: Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 2
Description: Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 3
Description: Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 3
Description: Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Vital Signs 4
Description: Changes in vital signs 4 - saturation - before, during and after the procedure were noted.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs 4
Description: Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
Study: NCT01423149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
Study: NCT03563885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
Study: NCT00846898

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cinnamon 2g per day for 12 weeks
Description: Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cinnamon 2g per day for 12 weeks
Description: Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
Study: NCT02153723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Study: NCT01332968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
Study: NCT01423149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
Study: NCT02319837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (No longer applicable in Open Label study period)
Description: Sugar pill to mimic enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Open Label
Study: NCT04265469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetic foot education
Description: Give Diabetic foot education via mobile phone
Study: NCT02693392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek Seed extract
Description: Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
Study: NCT01570868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Starting dose: 45 mg by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Starting dose: 45 mg by mouth once daily.
Study: NCT03361267

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori PCR test
Description: Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CLO test
Description: CLO test : negative --\> drop out CLO test : postive --\> bismuth containing quadruple therapy
Study: NCT01542580

Intervention type: DEVICE
Intervention: Vanguard SSK 360 with PS Bearing
Description: non-constrained tibial bearing

Intervention type: DEVICE
Intervention: Vanguard SSK 360 with PSC bearing
Description: constrained tibial bearing
Study: NCT00447317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BalanceWise-PD
Description: Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention control
Description: Standard peritoneal dialysis dietary education
Study: NCT03810391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: intravenous infusion of the same volume of physiological saline
Study: NCT01542580

Intervention type: DEVICE
Intervention: Vanguard DA 360
Description: Dual-articulation device, only cleared in EU

Intervention type: DEVICE
Intervention: Vanguard 360 TiNbN Femur with PS bearing
Description: non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur

Intervention type: DEVICE
Intervention: Vanguard 360 TiNbN Femur with PSC bearing
Description: constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
Study: NCT03810391

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: intravenous infusion of the same volume of physiological saline
Study: NCT06304038

Intervention type: DRUG
Intervention: Flu Vaccine
Description: Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
Study: NCT00508898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
Study: NCT03538821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact cod protein from fillet
Description: Intact cod protein from fillet 8 g protein daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact cod protein from residual material
Description: Intact cod protein from residual material, 8 g protein daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group receive tablet containing fillers
Study: NCT04211168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Lenvatinib
Description: Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop.
Study: NCT04151329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT1306 and BAT8001 2.4mg/kg
Description: Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT1306 and BAT8001 3.6mg/kg
Description: Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
Study: NCT00923936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
Study: NCT03469050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed released 400mg Tablet
Description: Rifaximin delayed released
Study: NCT04304287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation, 14 days before surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative autologous blood donation, 72 hours before surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Without preoperative blood donation
Study: NCT03410745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise.
Description: Moderate to heavy intensity resistance exercise consisting of leg press.
Study: NCT00780598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A.
Study: NCT00656695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iminoral
Description: Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
Study: NCT00712244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DisCoVisc
Description: Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuoVisc
Description: Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5
Description: Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
Study: NCT03469050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed released 400mg Tablet
Description: Rifaximin delayed released

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID + Placebo BID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo BID + Placebo BID
Study: NCT00969813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single 10 mg dose of CP-690,550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single 10 mg dose of CP-690,550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single 10 mg dose of CP-690,550
Study: NCT00586066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
Study: NCT00712244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amvisc Plus
Description: Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
Study: NCT01358253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
Study: NCT00656695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
Study: NCT02788292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: See arm description